Abstract
CD38 expression was investigated in 161 untreated patients with B-cell chronic lymphocytic leukemia (B-CLL). A score system, devised ad hoc by integrating the percentage and the mean fluorescence intensity (MFI) values of CD38(+) cells, indicated that B-CLL patients with a CD38 score < or =3 are characterized by a significantly longer survival compared to those with a CD38 score >3 (P=0.0026). Thirty-seven percent of patients with a CD38 score < or =3 and 58% of those with a score >3 were dead at 10 years. Multivariate analysis indicates that only the CD38 score successfully predicts survival (P=0.0028), with an estimated 3.8-fold greater risk of death for those cases with CD38 score >3.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
ADP-ribosyl Cyclase
-
ADP-ribosyl Cyclase 1
-
Antigens, CD*
-
Antigens, Differentiation / metabolism*
-
Female
-
Humans
-
Leukemia, Lymphocytic, Chronic, B-Cell / blood
-
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis
-
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
-
Lymphocytes / chemistry
-
Lymphocytes / pathology
-
Male
-
Membrane Glycoproteins
-
Middle Aged
-
Multivariate Analysis
-
NAD+ Nucleosidase / metabolism*
-
Predictive Value of Tests
-
Prognosis
-
Prospective Studies
-
Survival Analysis
Substances
-
Antigens, CD
-
Antigens, Differentiation
-
Membrane Glycoproteins
-
ADP-ribosyl Cyclase
-
CD38 protein, human
-
NAD+ Nucleosidase
-
ADP-ribosyl Cyclase 1